Annual Revenue Comparison: ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.

Biotech Revenue Trends: BioCryst vs. ImmunityBio (2014-2023)

__timestamp	BioCryst Pharmaceuticals, Inc.	ImmunityBio, Inc.
Wednesday, January 1, 2014	13608000	641000
Thursday, January 1, 2015	48257000	236000
Friday, January 1, 2016	26353000	44000
Sunday, January 1, 2017	25186000	45000
Monday, January 1, 2018	20653000	47000
Tuesday, January 1, 2019	48835000	2202000
Wednesday, January 1, 2020	17812000	605000
Friday, January 1, 2021	157170000	934000
Saturday, January 1, 2022	270827000	240000
Sunday, January 1, 2023	331412000	622000

Unleashing the power of data

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market position. Over the past decade, BioCryst Pharmaceuticals, Inc. has demonstrated a remarkable revenue trajectory, growing by over 2,300% from 2014 to 2023. In contrast, ImmunityBio, Inc. has experienced a more modest revenue increase, with fluctuations and a peak in 2019.

BioCryst's revenue surged significantly in 2023, reaching its highest point, while ImmunityBio's revenue remained relatively stable, with a notable spike in 2019. This divergence highlights the varying strategies and market conditions faced by these companies. As the biotech industry continues to evolve, these revenue trends offer valuable insights into the competitive landscape and the potential for future growth.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025